메뉴 건너뛰기




Volumn 9, Issue 11, 2015, Pages 1095-1105

Building a roadmap to biomarker qualification: Challenges and opportunities

Author keywords

biomarker; context of use; critical path innovation meeting; evidentiary considerations; international harmonization; letter of support; qualification; regulatory science; statistical considerations; submitter

Indexed keywords

BIOLOGICAL MARKER;

EID: 84947784661     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.90     Document Type: Review
Times cited : (47)

References (31)
  • 1
    • 0035100888 scopus 로고    scopus 로고
    • Biomarkers and surrogate end points: Preferred definitions and conceptual framework
    • Biomarkers Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
    • (2001) Clin. Pharmacol. Ther. , vol.69 , pp. 89-95
  • 4
    • 34047177929 scopus 로고    scopus 로고
    • Biomarker qualification pilot process at the US Food and Drug Administration
    • Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 9(1), E105-E108 (2007).
    • (2007) AAPS J. , vol.9 , Issue.1 , pp. E105-E108
    • Goodsaid, F.1    Frueh, F.2
  • 5
    • 80052059669 scopus 로고    scopus 로고
    • Qualifying biomarkers for use in drug development: A US Food and Drug Administration overview
    • Woodcock J, Buckman S, Goodsaid F et al. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. Expert Opin. Med. Diagn. 5(5), 369-374 (2011).
    • (2011) Expert Opin. Med. Diagn. , vol.5 , Issue.5 , pp. 369-374
    • Woodcock, J.1    Buckman, S.2    Goodsaid, F.3
  • 11
    • 84942484786 scopus 로고
    • Ridge regression: Biased estimation for nonorthogonal problems
    • Hocrl AE, Kennard R. Ridge regression: biased estimation for nonorthogonal problems. Technometrics 12, 55-67 (1970).
    • (1970) Technometrics , vol.12 , pp. 55-67
    • Hocrl, A.E.1    Kennard, R.2
  • 12
    • 85194972808 scopus 로고    scopus 로고
    • Regession shrinkage and selection via the lasso
    • Tibshirani R. Regession shrinkage and selection via the lasso. J. Royal Statistical Society Series B, 58, 267-288 (1996).
    • (1996) J. Royal Statistical Society Series B , vol.58 , pp. 267-288
    • Tibshirani, R.1
  • 13
    • 31744433060 scopus 로고    scopus 로고
    • Diagnosis using predictive probabilities without cut-offs
    • Choi YK, Johnson WO, Thurmond MC. Diagnosis using predictive probabilities without cut-offs. Stat. Med. 25(4), 699-717 (2006).
    • (2006) Stat. Med. , vol.25 , Issue.4 , pp. 699-717
    • Choi, Y.K.1    Johnson, W.O.2    Thurmond, M.C.3
  • 14
    • 84911962987 scopus 로고    scopus 로고
    • Multiplicity and replicability: Two sides of the same coin
    • Bretz F, Westfall P. Multiplicity and replicability: two sides of the same coin. Pharm. Stat. 13(6), 343-4 (2014).
    • (2014) Pharm. Stat. , vol.13 , Issue.6 , pp. 343-344
    • Bretz, F.1    Westfall, P.2
  • 16
    • 84947808036 scopus 로고    scopus 로고
    • Special statistical topics about biomarker qualification
    • Benain X. Special statistical topics about biomarker qualification, Webinar. (2014). http://c-path. org
    • (2014) Webinar
    • Benain, X.1
  • 17
    • 84947760914 scopus 로고    scopus 로고
    • Statistical issues associated with biomarker qualification
    • Schipper M. Statistical issues associated with biomarker qualification, Webinar. (2014). http://c-path. org
    • (2014) Webinar
    • Schipper, M.1
  • 18
  • 19
    • 33645061021 scopus 로고    scopus 로고
    • Retrospective validation of genomic biomarkers-what are the questions, challenges and strategies for developing useful relationships to clinical outcomes-workshop summary
    • Wang SJ, Cohen N, Katz DA, Ruano G, Shaw P, Spear B. Retrospective validation of genomic biomarkers-what are the questions, challenges and strategies for developing useful relationships to clinical outcomes-workshop summary. Pharmacogenomics J. 6, 82-88 (2006).
    • (2006) Pharmacogenomics J. , vol.6 , pp. 82-88
    • Wang, S.J.1    Cohen, N.2    Katz, D.A.3    Ruano, G.4    Shaw, P.5    Spear, B.6
  • 22
    • 77952138048 scopus 로고    scopus 로고
    • Renal biomarker qualification submission: A dialog between the FDA-EMEA and predictive safety testing consortium
    • Dieterle F, Sistare F, Goodsaid F et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotechnol. 28, 455-462 (2010).
    • (2010) Nat. Biotechnol. , vol.28 , pp. 455-462
    • Dieterle, F.1    Sistare, F.2    Goodsaid, F.3
  • 23
    • 77952164644 scopus 로고    scopus 로고
    • Urinary clusterin, cystatin C, ?2-microglobulin and total protein as markers to detect drug-induced kidney injury
    • Dieterle F, Perentes F, Cordier A et al. Urinary clusterin, cystatin C, ?2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat. Biotechnol. 28, 463-469 (2010).
    • (2010) Nat. Biotechnol. , vol.28 , pp. 463-469
    • Dieterle, F.1    Perentes, F.2    Cordier, A.3
  • 24
    • 80051703759 scopus 로고    scopus 로고
    • Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat
    • Harpur E, Ennulat D, Hoffman D et al. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicol. Sci. 122, 235-252 (2011).
    • (2011) Toxicol. Sci. , vol.122 , pp. 235-252
    • Harpur, E.1    Ennulat, D.2    Hoffman, D.3
  • 25
    • 84883451317 scopus 로고    scopus 로고
    • Qualification of cardiac troponins for nonclinical use: A regulatory perspective
    • Hausner EA, Hicks KA, Leighton JK et al. Qualification of cardiac troponins for nonclinical use: a regulatory perspective. Regul. Toxicol. Pharmacol. 67, 108-114 (2013).
    • (2013) Regul. Toxicol. Pharmacol. , vol.67 , pp. 108-114
    • Hausner, E.A.1    Hicks, K.A.2    Leighton, J.K.3
  • 26
    • 84927676328 scopus 로고    scopus 로고
    • Catalyzing the Critical Path Initiative: FDA's progress in drug development activities
    • Parekh A, Buckman-Garner S, McCune S et al. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities. Clin. Pharmacol. Ther. 97(3), 221-233 (2015).
    • (2015) Clin. Pharmacol. Ther. , vol.97 , Issue.3 , pp. 221-233
    • Parekh, A.1    Buckman-Garner, S.2    McCune, S.3
  • 27
    • 84947814165 scopus 로고    scopus 로고
    • FDA. LOS webpage. http://www. fda. gov
    • LOS Webpage
  • 28
    • 84947712877 scopus 로고    scopus 로고
    • FDA. CPIM Webpage. http://www. fda. gov
    • CPIM
  • 30
    • 84940540059 scopus 로고    scopus 로고
    • Biomarker qualification: Toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization
    • Amur S, LaVange L, Zineh I et al. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin. Pharmacol. Ther. 98(1), 34-46 (2015).
    • (2015) Clin. Pharmacol. Ther. , vol.98 , Issue.1 , pp. 34-46
    • Amur, S.1    LaVange, L.2    Zineh, I.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.